When to Switch to Subcutaneous Infliximab? The RE-WATCH Multicenter Study
Inflammatory Bowel Diseases · 01.12.2025 · 31 (12) · 3363-3369
DOI: 10.1093/ibd/izaf172 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 07.09.2025. Verfasst von Lorenzo Bertani und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Tuscany North-West ASL, Pontedera Hospital, Pontedera, Italy. Hauptthemen laut MEDLINE: Infliximab, Gastrointestinal Agents, Drug Substitution, Antibodies, Monoclonal. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
The infliximab (IFX) biosimilar, CT-P13, is available as an intravenous (IV) and subcutaneous (SC) formulation. Although current indications allow the transition from IV CT-P13 to SC CT-P13 after two IV administrations, some clinicians prefer to postpone switching until stable clinical remission has been achieved.
Methods
We evaluate the endoscopic response, treatment persistence, clinical remission, endoscopic remission, and safety profile after one year of treatment with IFX in patients switched from IV to SC after 6 weeks (early switch group) or after 6 months (late switch group).
Results
There were no statistical differences between the two groups after one year in terms of endoscopic response (71.4% vs 70.8%, P = .95), steroid-free clinical remission (62.5% vs 68.7%, P = .51), or IFX retention rate (75.0% vs 66.7%, P = .35). We observed higher endoscopic remission rates in early switch patients as compared to late switch patients; however, this trend was not significant (69.6% vs 52.1%, P = .07). A return to IV-IFX was required in 1 of 43 early switch patients and in 3 of 44 late switch patients (2.3% vs 6.8%, P = .31). Clinical indexes, fecal calprotectin and C-reactive protein (CRP) levels significantly decreased after one year regardless of group. Adverse events were also comparable between groups (4.5% vs 8.3%, P = .46).
Conclusions
Our study has shown that early switch from IV-IFX to SC-IFX at 6 weeks is effective in terms of clinical and endoscopic remission at one year yielding similar results to late switch at 6 months.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Tuscany North-West ASL, Pontedera Hospital, Pontedera, Italy.
- Unit of Gastroenterology, Department of Medical Sciences, University of Turin, Turin, Italy.
- Unit of Gastroenterology and Digestive Endoscopy, IRCCS Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
- IBD Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Italy.
ORCID-Profile: Lorenzo Bertani, Alessia Todeschini
Zitieren
APA
Bertani, L., Ribaldone, D. G., Bossa, F., Guerra, M., Annese, M., Manta, R., Armandi, A., Caviglia, G. P., Todeschini, A., & Variola, A. (2025). When to Switch to Subcutaneous Infliximab? The RE-WATCH Multicenter Study. Inflammatory Bowel Diseases, 31(12), 3363-3369. https://doi.org/10.1093/ibd/izaf172
Vancouver
Bertani L, Ribaldone DG, Bossa F, Guerra M, Annese M, Manta R, et al. When to Switch to Subcutaneous Infliximab? The RE-WATCH Multicenter Study. Inflammatory Bowel Diseases. 2025;31(12):3363-3369. doi:10.1093/ibd/izaf172
BibTeX
@article{Bertani2025,
author = {Bertani, Lorenzo and Ribaldone, Davide Giuseppe and Bossa, Fabrizio and Guerra, Maria and Annese, Monica and Manta, Raffaele and Armandi, Angelo and Caviglia, Gian Paolo and Todeschini, Alessia and Variola, Angela},
title = {When to Switch to Subcutaneous Infliximab? The RE-WATCH Multicenter Study},
journal = {Inflammatory Bowel Diseases},
year = {2025},
volume = {31},
number = {12},
pages = {3363--3369},
doi = {10.1093/ibd/izaf172}
}
EUVIMED